Benzinga's Top Upgrades with Color for May 3, 2012
Listed below are today's Top Upgrades at Benzinga:
Credit Suisse says, "We are upgrading the shares of MSCI from Neutral to Outperform. We view the recent weakness stemming from 1Q results as a buying opportunity, as the long-term secular tailwinds behind the story remain intact, while revenue and EPS growth is poised to accelerate in 2H12 and 2013. We believe MSCI is riding the secular wave of growth in int'l equity investing, growth in passive investing and the demand for more robust risk mgmt solutions - which should fuel long-term double digit revenue and EPS growth. Near-term, despite a continued challenging sales environment, earnings are poised to accelerate reflecting easier 2H12 comps, margin expansion, and deleveraging/refinancing benefits."
Credit Suisse comments, "We believe that the convergence of multiple technologies, which are core to the fourth-generation architecture, is having more dramatic effects across both the B2B and B2C CRM markets than any other applications segment, as organizations feel increasingly compelled to modernize and expand CRM applications. Furthermore, switching from post-recession caution to a growth posture, CEOs are focused on retaining existing customers and attracting new customers, which is placing increased attention on outdated CRM applications. As such, we believe that the industry stands at the beginning of a multiyear e-commerce, marketing, sales, service, and call center replacement cycle."
Oppenheimer stated, "Reports by cloud focused companies have confirmed continued strong enterprise buying patterns in 1Q12, and we believe with some help from the economy and the launch of new solutions (which we believe are very meaningful differentiators), TWTC is well positioned to exit 2012 at double-digit revenue growth. We see further improvements to the balance sheet from expected ramp in FCF generation LT."
All of Benzinga's Analyst Ratings news can be viewed here.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.